Algorithm for Identifying Chemotherapy/Biological Regimens for Metastatic Colon Cancer in SEER-Medicare

Medical Care

Volumn 53, Issue 8, 2015, Pages e58-e64

  Bikov, Kaloyan A ^a   Mullins, C Daniel ^a   Seal, Brian ^b   Onukwugha, Eberechukwu ^a   Hanna, Nader ^c  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b Bayer HealthCare Pharmaceuticals Inc   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

algorithm; biological; chemotherapy; metastatic colon cancer; regimens; SEER Medicare; treatment; treatment lines

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LEVOLEUCOVORIN; OXALIPLATIN; PANITUMUMAB; ANTINEOPLASTIC AGENT;

AFRICAN AMERICAN; AGED; ALGORITHM; ARTICLE; BIOLOGICAL THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CHARLSON COMORBIDITY INDEX; COLON CANCER; ETHNICITY; FEMALE; GENDER; GROUPS BY AGE; HISPANIC; HUMAN; MAJOR CLINICAL STUDY; MALE; MARRIED PERSON; MEDICARE; METASTATIC COLON CANCER; PRIORITY JOURNAL; RACE; SENSITIVITY ANALYSIS; URBAN AREA; VERY ELDERLY; ADJUVANT CHEMOTHERAPY; AGE; CANCER REGISTRY; COLONIC NEOPLASMS; METASTASIS; ORGANIZATION AND MANAGEMENT; UNITED STATES;

AGE FACTORS; AGED; AGED, 80 AND OVER; ALGORITHMS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; FEMALE; HUMANS; MALE; MEDICARE; NEOPLASM METASTASIS; SEER PROGRAM; UNITED STATES;

EID: 84937970669     PISSN: 00257079     EISSN: 15371948     Source Type: Journal    
DOI: 10.1097/MLR.0b013e31828fad9f     Document Type: Article

References (19)

1. Warren Joan L, Klabunde Carrie N, Schrag Deborah, et al. Overview of the SEER-Medicare Data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40: IV-3-IV-18.
2. Bach Peter B, Edward Guadagnoli, Schrag Deborah, et al. Patient demographic and socioeconomic characteristics in the SEER-Medicare database: applications and limitations. Med Care. 2002;40:IV-19-IV-25.
3. Warren Joan L, Harlan Linda C, Fahey Angela, et al. Utility of the SEER-Medicare data to identify chemotherapy use. Med Care. 2002; 40:IV-55-IV-61.
4. Hsiao FY, Mullins CD, Onukwugha E, et al. Comparative effectiveness of different chemotherapeutic regimens on survival of people aged 66 and older with stage III colon cancer: a real world analysis using Surveillance, Epidemiology, and End Results-Medicare data. J Am Geriatr Soc. 2011;59:1717-1723.
5. Sanoff HK, Carpenter WR, Martin CF, et al. Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer. J Natl Cancer Inst. 2012;104: 211-227.
6. Sanoff HK, Carpenter WR, Freburger J, et al. Comparison of adverse events during 5-fluorouracil versus 5-fluorouracil/oxaliplatin adjuvant chemotherapy for stage III colon cancer: a population-based analysis. Cancer. 2012;118:4309-4320.
7. Iwashyna TJ, Lamont EB. Effectiveness of adjuvant fluorouracil in clinical practice: a population-based cohort study of elderly patients with stage III colon cancer. J Clin Oncol. 2002;20:3992-3998.
8. Meyerhardt JA, Li L, Sanoff HK, et al. Effectiveness of bevacizumab with first-line combination chemotherapy for Medicare patients with stage IV colorectal cancer. J Clin Oncol. 2012;30:608-615.
9. Obeidat NA, Pradel FG, Zuckerman IH, et al. Outcomes of irinotecanbased chemotherapy regimens in elderly Medicare patients with metastatic colorectal cancer. Am J Geriatr Pharmacother. 2009;7: 343-354.
10. Mack CD, Carpenter W, Meyer AM, et al. Racial disparities in receipt and comparative effectiveness of oxaliplatin for stage III colon cancer in older adults. Cancer. 2012;118:2925-2934.
11. Obeidat NA, Pradel FG, Zuckerman IH, et al. Racial/ethnic and age disparities in chemotherapy selection for colorectal cancer. Am J Manag Care. 2010;16:515-522.
12. Lund JL, Stürmer T, Harlan LC, et al. Identifying specific chemotherapeutic agents in Medicare data: a validation study. Med Care. 2013;51:e27-e34.
13. Griffiths RI, Gleeson ML, Mikhael J, et al. Impact on medical cost, cumulative survival, and cost-effectiveness of adding rituximab to firstline chemotherapy for follicular lymphoma in elderly patients: an observational cohort study based on SEER-Medicare. J Cancer Epidemiol. 2012;2012:978391.
14. Meyerhardt JA, Li L, Sanoff HK, et al. Effectiveness of bevacizumab with first-line combination chemotherapy for Medicare patients with stage IV colorectal cancer. J Clin Oncol. 2012;30:608-615.
15. Griffiths R, Mikhael J, Gleeson M, et al. Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma. Blood. 2011;118:4808-4816.
16. Davidoff AJ, Tang M, Seal B, et al. Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol. 2010;28:2191-2197.
17. Stokes ME, Muehlenbein CE, Marciniak MD, et al. Neutropeniarelated costs in patients treated with first-line chemotherapy for advanced non-small cell lung cancer. J Manag Care Pharm. 2009;15: 669-682.
18. Lang K, Marciniak MD, Faries D, et al. Trends and predictors of first-line chemotherapy use among elderly patients with advanced nonsmall cell lung cancer in the United States. Lung Cancer. 2009;63: 264-270.
19. National Comprehensive Cancer Network [NCCN Guidelines Web site]. 2012. Available at: http://www.nccn.org/professionals/physician-gls/f-guidelines.asp. Accessed November 8, 2012.